Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis GAITHERSBURG, Md., July 02, ...
GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and ...
LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO ® ...
The FDA has approved an abbreviated new drug application for naloxone hydrochloride nasal spray, paving the way for the opioid overdose treatment to be available without a prescription. According to a ...
Hikma announced the shelf-life extension of Kloxxado (naloxone HCl) nasal spray 8 mg from 24 to 36 months. Kloxxado packaging has been updated with 36-month dating, starting with product manufactured ...
GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN ® ...
The three-year shelf-life extension improves naloxone access for communities and first responders who continue to fight the growing opioid epidemic ALLEGAN, Mich., April 2, 2025 /PRNewswire/ -- ...
The US Food and Drug Administration (FDA) has granted final approval for the first generic naloxone hydrochloride nasal spray (Narcan, Teva Pharmaceuticals) that can stop or reverse the effects of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback